Significant history of cardiovascular disease
Uncontrolled or significant cardiovascular disease
Evidence of clinically significant cardiovascular and respiratory conditions
Significant cardiovascular disease;
Significant cardiovascular disease or active pulmonary disease
Clinically significant cardiovascular disease
Significant cardiovascular disease
Significant cardiovascular disease
Significant cardiovascular/cerebrovascular disease within 6 months prior to Day 1 of study drug administration
Significant cardiovascular disease
Current severe, uncontrolled systemic disease (for example [e.g.] clinically significant cardiovascular, pulmonary, or metabolic disease)
Significant cardiovascular disease.
Clinically significant cardiovascular disease
Significant cardiovascular disease
Any significant cardiovascular events within 6 months prior to study entry
History of a significant cardiovascular illness
Significant cardiovascular disease
Uncontrolled or significant cardiovascular diseases
Uncontrolled or significant cardiovascular disease
Subjects with significant or uncontrolled cardiovascular disease
Significant cardiovascular disease
Clinically significant cardiovascular disease or condition
Patients with clinically significant cardiovascular disease, thromboembolic disease, or significant risk of bleeding.
Uncontrolled or significant cardiovascular disease
Significant cardiovascular disease or ECG abnormalities.
Currently active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first dose
Clinically significant cardiovascular or pulmonary disease
Significant known cardiovascular impairment.
Uncontrolled or significant cardiovascular disease.
History of clinically significant cardiovascular disease
Clinically significant cardiovascular disease.
Clinically significant cardiovascular disease or condition
Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)
History of clinically significant cardiovascular disease;
Uncontrolled or significant cardiovascular disease
Clinically significant cardiovascular disease.
Clinically significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Clinically significant cardiovascular disease.
Clinically significant cardiovascular disease
Cardiovascular Function: Adequate cardiovascular function in the opinion of the Investigator with no clinically significant uncontrolled cardiovascular disease.
Clinically significant cardiovascular disease or condition
Significant cardiovascular disease, such as
Significant cardiovascular disease within 3 months prior to Day 1 of Cycle 1
Subjects who developed cardiovascular disease within 24 weeks prior to study entry, which is deemed to be clinically significant by the Investigator.
Has uncontrolled or significant cardiovascular disease
Known clinically significant cardiovascular disease or condition.
Have a significant electrocardiogram finding or cardiovascular disease
Currently active, clinically significant cardiovascular disease or a history of myocardial infarction within 6 months prior to inclusion
Clinically significant, uncontrolled, cardiovascular disease.
History of clinically-significant cardiovascular disease.
Significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Significant cardiovascular disease
Clinically significant cardiovascular disease
Clinically significant cardiovascular risk.
Uncontrolled or significant cardiovascular disease
Clinically significant (i.e., active) cardiovascular disease
Significant cardiovascular disease.
Significant cardiovascular disease within 6 months of screening.
Significant cardiovascular disease within 6 months of screening.
Significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Significant cardiovascular disease.
Significant cardiovascular disease
Clinically significant cardiovascular disease
Subject has clinically significant cardiovascular disease.
Clinically significant cardiovascular disease;
Clinically symptomatic and uncontrolled cardiovascular disease
Significant cardiovascular disease
Have significant, uncontrolled, or active cardiovascular disease, as defined by the study protocol.
Patients with clinically significant cardiovascular disease.
History of autoimmune disease, significant pulmonary disease, or significant cardiovascular disease
Significant cardiovascular or liver disease
Significant history of cardiovascular disease
Patients with clinically significant, uncontrolled cardiovascular disease
Significant cardiovascular disease or significant pulmonary disease
Significant cardiovascular diseases
Significant cardiovascular or pulmonary disease
Subjects with clinically significant cardiovascular disease.
Subjects with clinically significant cardiovascular disease. This includes:
Significant cardiovascular disease
Currently active, clinically significant cardiovascular disease.
Currently active, clinically significant cardiovascular disease
Significant cardiovascular disease.
Significant cardiovascular disease
Clinically significant cardiovascular disease;
Clinically significant cardiovascular disease
Significant cardiovascular disease
Clinically significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Clinically significant (that is, active) cardiovascular disease
Impaired cardiovascular function or clinically significant cardiovascular diseases
Impaired cardiovascular function or clinically significant cardiovascular diseases.
Impaired cardiovascular function or clinically significant cardiovascular diseases
Have significant or active cardiovascular disease
Currently active, clinically significant cardiovascular disease
Active cardiovascular disease or significant history thereof.
Significant cardiovascular disease.
Clinically significant cardiovascular disease;
DONOR: Significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
History (within the last 6 months) of significant cardiovascular disease.
Significant or uncontrolled cardiovascular disease
Significant cardiovascular disease
Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease)
History of significant cardiovascular disease, defined as:
Clinically significant cardiovascular disease.
Significant cardiovascular disease
History of significant cardiovascular disease will be excluded
Currently active, clinically significant cardiovascular disease or myocardial infarction within 6 months of screening
Significant history of cardiovascular disease
Clinically significant cardiovascular impairment
Significant cardiovascular disease
Subject has a significant cardiovascular disease
Significant cardiovascular diseases
Clinically significant cardiovascular risk
Clinically significant cardiovascular disease
Significant or uncontrolled cardiovascular disease or bleeding disorder
Uncontrolled or significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Uncontrolled hypertension or clinically significant cardiovascular disease
Significant cardiovascular impairment, defined as:
Impaired cardiovascular function or clinically significant cardiovascular diseases
Uncontrolled or significant cardiovascular disease
History of clinically-significant cardiovascular disease
Significant history of cardiovascular disease
History of clinically significant cardiovascular disease, gastrointestinal disorder, or significant pulmonary compromise.
Patients with known significant active cardiovascular or pulmonary disease at the time of study entry are ineligible
Significant cardiovascular disease
History of clinically significant cardiovascular disease
Uncontrolled or significant cardiovascular disease
Clinically significant cardiac/cardiovascular disease, or pulmonary compromise
Currently active clinically significant cardiovascular disease or history of myocardial infarction within 6 months of first dose
